Xanthomas and hyperlipidemia in a human immunodeficiency virus-infected child receivng highly active antiretroviral therapy.
An 8-year-old perinatally HIV-infected boy developed xanthomas secondary to highly active antiretroviral therapy-induced hyperlipidemia. This is a phenomenon previously not reported in HIV-infected children. The case illustrates the difficulty in managing an emerging complication, extreme hyperlipidemia, in children receiving highly active antiretroviral therapy because of limited pediatric experience with lipid-lowering agents and the likely need for lifelong treatment.
Babl
Franz E
FE
Maxwell Finland Laboratory for Infectious Diseases, Boston Medical Center, MA, USA.
Regan
Anne-Marie
AM
Pelton
Stephen I
SI
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D002648:Child; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced* / Q000150:complications*; D008297:Male; D014973:Xanthomatosis / Q000150:complications*
D019380:Anti-HIV Agents